These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 27515694

  • 1. Pro: STOP immunosuppression in IgA nephropathy?
    Pozzi C.
    Nephrol Dial Transplant; 2016 Nov; 31(11):1766-1770. PubMed ID: 27515694
    [Abstract] [Full Text] [Related]

  • 2. Con: STOP immunosuppression in IgA nephropathy.
    Rauen T, Eitner F, Fitzner C, Floege J.
    Nephrol Dial Transplant; 2016 Nov; 31(11):1771-1774. PubMed ID: 27515693
    [Abstract] [Full Text] [Related]

  • 3. Moderator's view: Treatment of IgA nephropathy-getting comfortable with uncertainty.
    Glassock RJ.
    Nephrol Dial Transplant; 2016 Nov; 31(11):1776-1780. PubMed ID: 27515695
    [Abstract] [Full Text] [Related]

  • 4. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.
    Rauen T, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J.
    J Am Soc Nephrol; 2018 Jan; 29(1):317-325. PubMed ID: 29042456
    [Abstract] [Full Text] [Related]

  • 5. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
    Nagy J, Sági B, Máté J, Vas T, Kovács T.
    Orv Hetil; 2017 Dec; 158(49):1946-1952. PubMed ID: 29199436
    [Abstract] [Full Text] [Related]

  • 6. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
    Eitner F, Ackermann D, Hilgers RD, Floege J.
    J Nephrol; 2008 Dec; 21(3):284-9. PubMed ID: 18587715
    [Abstract] [Full Text] [Related]

  • 7. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.
    Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J, STOP-IgAN Investigators.
    N Engl J Med; 2015 Dec 03; 373(23):2225-36. PubMed ID: 26630142
    [Abstract] [Full Text] [Related]

  • 8. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S, Li JP.
    Trials; 2020 Jan 06; 21(1):31. PubMed ID: 31907076
    [Abstract] [Full Text] [Related]

  • 9. Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial.
    Cheung CK, Barratt J.
    Kidney Int; 2020 Oct 06; 98(4):836-838. PubMed ID: 32998815
    [Abstract] [Full Text] [Related]

  • 10. Immunosuppression in IgA Nephropathy: Guideline Medicine Versus Personalized Medicine.
    Feehally J.
    Semin Nephrol; 2017 Sep 06; 37(5):464-477. PubMed ID: 28863793
    [Abstract] [Full Text] [Related]

  • 11. Treatment of IgA nephropathy with renal insufficiency.
    Pozzi C, Sarcina C, Ferrario F.
    J Nephrol; 2016 Aug 06; 29(4):551-8. PubMed ID: 26743078
    [Abstract] [Full Text] [Related]

  • 12. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.
    Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R, VALIGA study of the ERA-EDTA Immunonephrology Working Group.
    J Am Soc Nephrol; 2015 Sep 06; 26(9):2248-58. PubMed ID: 25677392
    [Abstract] [Full Text] [Related]

  • 13. Steroid therapy in children with IgA nephropathy.
    Cambier A, Boyer O, Deschenes G, Gleeson J, Couderc A, Hogan J, Robert T.
    Pediatr Nephrol; 2020 Mar 06; 35(3):359-366. PubMed ID: 30778826
    [Abstract] [Full Text] [Related]

  • 14. Treatment of IgA nephropathy.
    Pozzi C.
    J Nephrol; 2016 Feb 06; 29(1):21-5. PubMed ID: 26577268
    [Abstract] [Full Text] [Related]

  • 15. Immunosuppressive therapy for active IgA nephropathy is effective and safe, even in "elderly" patients.
    Fukuda M, Hotta O, Mizuno M, Ogiyama Y, Ohte N.
    Clin Exp Nephrol; 2016 Dec 06; 20(6):832-834. PubMed ID: 27443481
    [Abstract] [Full Text] [Related]

  • 16. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.
    Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Budde K, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J, STOP-IgAN Investigators.
    Kidney Int; 2020 Oct 06; 98(4):1044-1052. PubMed ID: 32450154
    [Abstract] [Full Text] [Related]

  • 17. Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy.
    Lennartz DP, Seikrit C, Wied S, Fitzner C, Eitner F, Hilgers RD, Rauen T, Floege J.
    J Nephrol; 2020 Dec 06; 33(6):1231-1239. PubMed ID: 32856272
    [Abstract] [Full Text] [Related]

  • 18. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
    Hou JH, Le WB, Chen N, Wang WM, Liu ZS, Liu D, Chen JH, Tian J, Fu P, Hu ZX, Zeng CH, Liang SS, Zhou ML, Zhang HT, Liu ZH.
    Am J Kidney Dis; 2017 Jun 06; 69(6):788-795. PubMed ID: 28215945
    [Abstract] [Full Text] [Related]

  • 19. An update on the treatment of IgA nephropathy.
    Barbour S, Feehally J.
    Curr Opin Nephrol Hypertens; 2017 Jul 06; 26(4):319-326. PubMed ID: 28399021
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.
    Chakera A, MacEwen C, Bellur SS, Chompuk LO, Lunn D, Roberts ISD.
    J Nephrol; 2016 Jun 06; 29(3):367-375. PubMed ID: 26318019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.